Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle?
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.27, sa.2, ss.450-452, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Editöre Mektup
- Cilt numarası: 27 Sayı: 2
- Basım Tarihi: 2021
- Doi Numarası: 10.1177/1078155220988753
- Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Sayfa Sayıları: ss.450-452
- Anahtar Kelimeler: COVID-19, cancer, chemotherapy
- Ankara Üniversitesi Adresli: Evet
Özet
Cancer patients under active chemotherapy are more vulnerable to coronavirus disease 19 (COVID-19). There are still some controversies regarding routine polymerase chain reaction testing of asymptomatic cancer patients before chemotherapy cycles. Despite a lack of data, Al-Shamsi et al. showed higher COVID-19 positivity rate among asymptomatic cancer patients. Furthermore, mortality rate was higher in this group of patients. There is no high evidence-based recommendation from the cancer societies for testing asymptomatic patients before each chemotherapy cycle. In this commentary, we assessed the current publications and guidelines regarding this issue.